<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:07:54Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6003645" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:6003645</identifier><datestamp>2018-06-26</datestamp><setSpec>emboj</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EMBO J</journal-id>
      <journal-id journal-id-type="iso-abbrev">EMBO J</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1460-2075</journal-id>
      <journal-id journal-id-type="publisher-id">EMBJ</journal-id>
      <journal-id journal-id-type="hwp">embojnl</journal-id>
      <journal-title-group>
        <journal-title>The EMBO Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0261-4189</issn>
      <issn pub-type="epub">1460-2075</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC6003645</article-id>
      <article-id pub-id-type="pmcid">PMC6003645</article-id>
      <article-id pub-id-type="pmc-uid">6003645</article-id>
      <article-id pub-id-type="pmid">29789392</article-id>
      <article-id pub-id-type="doi">10.15252/embj.201899543</article-id>
      <article-id pub-id-type="publisher-id">EMBJ201899543</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>
<styled-content style="fixed-case">FAM</styled-content>35A associates with <styled-content style="fixed-case">REV</styled-content>7 and modulates <styled-content style="fixed-case">DNA</styled-content>Â damage responses of normal and <styled-content style="fixed-case">BRCA</styled-content>1âdefective cells</article-title>
        <alt-title alt-title-type="left-running-head">Junya Tomida <italic>etÂ al</italic></alt-title>
      </title-group>
      <contrib-group>
        <contrib id="embj201899543-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Tomida</surname>
            <given-names>Junya</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0813-5757</contrib-id>
          <address>
            <email>jtomida@mdanderson.org</email>
          </address>
          <xref ref-type="aff" rid="embj201899543-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0002" contrib-type="author">
          <name>
            <surname>Takata</surname>
            <given-names>Keiâichi</given-names>
          </name>
          <xref ref-type="aff" rid="embj201899543-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0003" contrib-type="author">
          <name>
            <surname>Bhetawal</surname>
            <given-names>Sarita</given-names>
          </name>
          <xref ref-type="aff" rid="embj201899543-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0004" contrib-type="author">
          <name>
            <surname>Person</surname>
            <given-names>Maria D</given-names>
          </name>
          <xref ref-type="aff" rid="embj201899543-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0005" contrib-type="author">
          <name>
            <surname>Chao</surname>
            <given-names>HsuehâPing</given-names>
          </name>
          <xref ref-type="aff" rid="embj201899543-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0006" contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Dean G</given-names>
          </name>
          <xref ref-type="aff" rid="embj201899543-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="embj201899543-cr-0007" contrib-type="author" corresp="yes">
          <name>
            <surname>Wood</surname>
            <given-names>Richard D</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9495-6892</contrib-id>
          <address>
            <email>rwood@mdanderson.org</email>
          </address>
          <xref ref-type="aff" rid="embj201899543-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="embj201899543-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Epigenetics &amp; Molecular Carcinogenesis</named-content>
<institution>The University of Texas MD Anderson Cancer Center</institution>
<named-content content-type="city">Smithville</named-content>
<named-content content-type="country-part">TX</named-content>
<country country="US">USA</country>
</aff>
      <aff id="embj201899543-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Proteomics Facility</named-content>
<institution>University of Texas at Austin</institution>
<named-content content-type="city">Austin</named-content>
<named-content content-type="country-part">TX</named-content>
<country country="US">USA</country>
</aff>
      <aff id="embj201899543-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Pharmacology and Therapeutics</named-content>
<institution>Roswell Park Cancer Institute</institution>
<named-content content-type="city">Buffalo</named-content>
<named-content content-type="country-part">NY</named-content>
<country country="US">USA</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>
Corresponding author. Tel: +1 512 237 6433; Eâmail: <email>jtomida@mdanderson.org</email><break/>
Corresponding author. Tel: +1 512 237 9431; Eâmail: <email>rwood@mdanderson.org</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>5</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>6</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>22</day>
        <month>5</month>
        <year>2018</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>37</volume>
      <issue>12</issue>
      <issue-id pub-id-type="doi">10.1002/embj.v37.12</issue-id>
      <elocation-id>e99543</elocation-id>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>4</month>
          <year>2018</year>
        </date>
        <date date-type="rev-recd">
          <day>03</day>
          <month>5</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>5</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 EMBO <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2018 The Authors. Published under the terms of the CC BY 4.0 license</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EMBJ-37-e99543.pdf"/>
      <abstract id="embj201899543-abs-0001">
        <title>Abstract</title>
        <p>To exploit vulnerabilities of tumors, it is urgent to identify associated defects in genome maintenance. One unsolved problem is the mechanism of regulation of <styled-content style="fixed-case">DNA</styled-content> doubleâstrand break repair by <styled-content style="fixed-case">REV</styled-content>7 in complex with 53<styled-content style="fixed-case">BP</styled-content>1 and <styled-content style="fixed-case">RIF</styled-content>1, and its influence on repair pathway choice between homologous recombination and nonâhomologous endâjoining. We searched for <styled-content style="fixed-case">REV</styled-content>7âassociated factors in human cells and found <styled-content style="fixed-case">FAM</styled-content>35A, a previously unstudied protein with an unstructured Nâterminal region and a Câterminal region harboring three <styled-content style="fixed-case">OB</styled-content>âfold domains similar to singleâstranded <styled-content style="fixed-case">DNA</styled-content>âbinding protein <styled-content style="fixed-case">RPA</styled-content>, as novel interactor of <styled-content style="fixed-case">REV</styled-content>7/<styled-content style="fixed-case">RIF</styled-content>1/53<styled-content style="fixed-case">BP</styled-content>1. <styled-content style="fixed-case">FAM</styled-content>35A reâlocalized in damaged cell nuclei, and its knockdown caused sensitivity to <styled-content style="fixed-case">DNA</styled-content>âdamaging agents. In a <styled-content style="fixed-case">BRCA</styled-content>1âmutant cell line, however, depletion of <styled-content style="fixed-case">FAM</styled-content>35A increased resistance to camptothecin, suggesting that <styled-content style="fixed-case">FAM</styled-content>35A participates in processing of <styled-content style="fixed-case">DNA</styled-content> ends to allow more efficient <styled-content style="fixed-case">DNA</styled-content> repair. We found <styled-content style="fixed-case">FAM</styled-content>35A absent in one widely used <styled-content style="fixed-case">BRCA</styled-content>1âmutant cancer cell line (<styled-content style="fixed-case">HCC</styled-content>1937) with anomalous resistance to <styled-content style="fixed-case">PARP</styled-content> inhibitors. A survey of <styled-content style="fixed-case">FAM</styled-content>35A alterations revealed that the gene is altered at the highest frequency in prostate cancers (up to 13%) and significantly less expressed in metastatic cases, revealing promise for <styled-content style="fixed-case">FAM</styled-content>35A as a therapeutically relevant cancer marker.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="embj201899543-kwd-0001">camptothecin</kwd>
        <kwd id="embj201899543-kwd-0002">cisplatin</kwd>
        <kwd id="embj201899543-kwd-0003"><styled-content style="fixed-case">DNA</styled-content> repair</kwd>
        <kwd id="embj201899543-kwd-0004">olaparib</kwd>
        <kwd id="embj201899543-kwd-0005">prostate cancer</kwd>
      </kwd-group>
      <kwd-group kwd-group-type="subject-categories">
        <title>Subject Categories</title>
        <kwd>Cancer</kwd>
        <kwd>DNA Replication, Repair &amp; Recombination</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Grady F. Saunders Ph.D</funding-source>
        </award-group>
        <award-group>
          <funding-source>Distinguished Research Professorship</funding-source>
        </award-group>
        <award-group>
          <funding-source>Center for Radiation Oncology Research</funding-source>
        </award-group>
        <award-group>
          <funding-source>HHS|NIH|National Cancer Institute (NCI)</funding-source>
          <award-id>CA132840</award-id>
          <award-id>CA097175</award-id>
          <award-id>CA193124</award-id>
          <award-id>CA212556</award-id>
          <award-id>P30âCA016672</award-id>
        </award-group>
        <award-group>
          <funding-source>UT|University of Texas MD Anderson Cancer Center (MD Anderson)</funding-source>
        </award-group>
        <award-group>
          <funding-source>Cancer Prevention and Research Institute of Texas (CPRIT)</funding-source>
          <award-id>RP130297</award-id>
          <award-id>RP120348</award-id>
          <award-id>RP170002</award-id>
          <award-id>RP110782</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="10"/>
        <table-count count="3"/>
        <page-count count="14"/>
        <word-count count="9544"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>embj201899543</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>15 June 2018</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.1.1 mode:remove_FC converted:15.06.2018</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="embj201899543-cit-1001">
<source xml:lang="en">The EMBO Journal</source> (<year>2018</year>) <volume>37</volume>: <elocation-id>e99543</elocation-id>
</mixed-citation>
</p>
    </notes>
  </front>
  <body>
    <sec id="embj201899543-sec-0001">
      <title>Introduction</title>
      <p>REV7 is a multifunctional protein encoded by the <italic>MAD2L2</italic> gene in human cells. REV7 acts as an interaction module in several cellular pathways. One of its functions is as a component of DNA polymerase Î¶, where it serves as bridge between the Pol Î¶ catalytic subunit REV3L and the REV1 protein. A dimer of REV7 binds to two adjacent sites in REV3L by grasping a peptide of REV3L with a âsafetyâbeltâ loop (Hara <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0017" ref-type="ref">2010</xref>; Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0045" ref-type="ref">2015</xref>). REV7 protein is an order of magnitude more abundant than REV3L (Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0045" ref-type="ref">2015</xref>) and has additional functions and protein partners including chromatinâassociated and postâtranslational modification proteins (Medendorp <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0033" ref-type="ref">2009</xref>; Vermeulen <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0048" ref-type="ref">2010</xref>; Itoh <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0021" ref-type="ref">2011</xref>; Listovsky &amp; Sale, <xref rid="embj201899543-bib-0029" ref-type="ref">2013</xref>; Pirouz <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0037" ref-type="ref">2013</xref>; Hara <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0018" ref-type="ref">2017</xref>). Complete ablation of REV7 gives rise to mice with defects in primary germ cells (Pirouz <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0037" ref-type="ref">2013</xref>; Watanabe <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0050" ref-type="ref">2013</xref>). Recently, studies uncovered a function of REV7 as a DNA resection inhibitor, limiting genomic repair by an unknown mechanism (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>). Although BRCA1âmutant cells are defective in homologous recombination, these studies found that one mode to partially restore recombination activity is by inactivation of REV7. It was proposed that REV7, together with 53BP1 and RIF1, inhibits 5â² DNA end resection to promote nonâhomologous endâjoining at the expense of homologous recombination.</p>
      <p>To investigate novel functions and pathways involving REV7, we identified proteins associated with REV7 <italic>inÂ vivo</italic>. We report here an analysis of a previously uncharacterized REV7âinteracting protein, FAM35A. We discovered that FAM35A is a novel factor that modulates the DNA damage sensitivity of normal and BRCA1âdefective cells. Our analysis reveals that the Câterminal half of FAM35A contains three OBâfold domains similar to those in the singleâstranded DNAâbinding protein RPA large subunit. FAM35A has a disordered Nâterminal portion, containing sites of DNA damageâdependent postâtranslational modification. Moreover, the <italic>FAM35A</italic> gene is deleted at an unusually high rate in prostate cancers, and in cells from at least one wellâstudied BRCA1âdefective breast cancer case. FAM35A is more weakly expressed in metastatic prostate cancers, suggesting it as an important marker for outcome and therapeutic decisions.</p>
    </sec>
    <sec id="embj201899543-sec-0002">
      <title>Results and Discussion</title>
      <sec id="embj201899543-sec-0003">
        <title>FAM35A interacts with REV7, 53BP1, and RIF1 <italic>inÂ vivo</italic>
</title>
        <p>To isolate proteins associated with REV7, we engineered HeLa S3 cells that stably express REV7 with a Câterminal FLAGâHA epitope tag (REV7âFH). REV7âFH was sequentially immunoprecipitated from nuclear extract using FLAG and HA antibody beads (Ikura <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0020" ref-type="ref">2007</xref>). This purified complex was separated by gradient gel electrophoresis, and associated proteins from gel sections were identified by LCâMS/MS. We confirmed association with previously identified REV7âbinding proteins including GLP (Nakatani &amp; Ogryzko, <xref rid="embj201899543-bib-0034" ref-type="ref">2003</xref>; Pirouz <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0037" ref-type="ref">2013</xref>), G9A (Pirouz <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0037" ref-type="ref">2013</xref>), CAMP (Itoh <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0021" ref-type="ref">2011</xref>), GTF2I (Fattah <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0011" ref-type="ref">2014</xref>), POGZ (Vermeulen <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0048" ref-type="ref">2010</xref>), and HP1Î± (Vermeulen <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0048" ref-type="ref">2010</xref>) (FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>A and TableÂ <xref rid="embj201899543-tbl-0001" ref-type="table-wrap">1</xref>). The highestâranking previously unstudied association was with the uncharacterized FAM35A protein (FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>A).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>Identification of <styled-content style="fixed-case">REV</styled-content>7â or <styled-content style="fixed-case">FAM</styled-content>35Aâassociated proteins</title>
            <p>Protein complexes were sequentially immunoprecipitated (using FLAG and HA antibody beads) from nuclear extracts of HeLa S3 cell lines stably expressing Câterminally FLAGâHAâtagged REV7 (REV7âFH) or (Nâterminally FLAGâHAâtaggedâFAM35A (FHâFAM35A). 
<list list-type="simple" id="embj201899543-list-0002"><list-item><label>A, B</label><p>REV7 complex (A) and FAM35A complex (B); associated proteins were identified by mass spectrometry. The FHâFAM35A complex was purified from HeLa S3 nuclear extracts after 18Â h exposure to MMC (100Â ng/ml). Proteins labeled in blue are previously published REV7âbinding partners. Proteins labeled in red are involved in endâjoining pathways of DSB repair. 4â20% gradient gels were stained with SYPRO Ruby.</p></list-item><list-item><label>C</label><p>FHâFAM35A was coâtransfected into human 293T cells with GFP empty vector (control), GFPâ53BP1 or GFPâRIF1. Fortyâeight hours after transfection, cell lysates were made and used for immunoprecipitation with GFP antibody beads. After electrophoretic transfer of proteins, the membrane was cut into three sections to separate proteins &gt;Â 250Â kDa (GFP as GFPâ53BP1 and GFPâRIF1), 37â250Â kDa (Î±âtubulin), and &lt;Â 37Â kDa (GFP as control) and immunoblotted with the indicated antibodies. Results for the input and immunoprecipitation (IP) product after gel electrophoresis are shown. The asterisk (*) in the IP lane marks degraded or truncated forms of 53BP1 and RIF1.</p></list-item></list>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="EMBJ-37-e99543-g002"/>
        </fig>
        <table-wrap id="embj201899543-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Identification of FAM35A with previously reported proteins in a REV7âassociated complex</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Protein</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Accession number (UniProtKB)</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Molecular weight</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Spectral counts</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Unique peptides</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">REV7</td>
                <td align="left" rowspan="1" colspan="1">Q9UI95|MD2L2_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">24Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">453</td>
                <td align="char" char="." rowspan="1" colspan="1">15</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">FAM35A</td>
                <td align="left" rowspan="1" colspan="1">Q86V20â2|FA35A_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">92Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">74</td>
                <td align="char" char="." rowspan="1" colspan="1">23</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">GLP</td>
                <td align="left" rowspan="1" colspan="1">Q9H9B1|EHMT1_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">141Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">9</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">G9A</td>
                <td align="left" rowspan="1" colspan="1">Q96KQ7|EHMT2_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">135Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">7</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">CAMP</td>
                <td align="left" rowspan="1" colspan="1">Q96JM3|ZN828_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">89Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">127</td>
                <td align="char" char="." rowspan="1" colspan="1">29</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">GTF2I</td>
                <td align="left" rowspan="1" colspan="1">B4DH52|B4DH52_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">112Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">1780</td>
                <td align="char" char="." rowspan="1" colspan="1">88</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">POGZ</td>
                <td align="left" rowspan="1" colspan="1">Q7Z3K3| POGZ_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">154Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">147</td>
                <td align="char" char="." rowspan="1" colspan="1">31</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">HP1Î±</td>
                <td align="left" rowspan="1" colspan="1">P45973|CBX5_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">22Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">8</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn fn-type="equal" id="embj201899543-note-0001">
              <p>The immunoprecipitated sample was separated on a denaturing polyacrylamide gel, and proteins from gel sections of approximately equal size were identified by LCâMS/MS. FAM35A was a top specific hit, together with previously identified REV7âassociated proteins. GTF2I (TFIIâI) is likely a nonâsignificant association as it is an abundant protein frequently found in control experiments with agarose supports and FlagâHis tags (<ext-link ext-link-type="uri" xlink:href="http://www.crapome.org">http://www.crapome.org</ext-link>), but it is included here for reference, as it was previously reported to interact with REV7 (Fattah <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0011" ref-type="ref">2014</xref>).</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>To validate the association, a reciprocal experiment was performed by constructing a HeLa S3 cell line stably expressing FAM35A with an Nâterminal FLAGâHA tag (FHâFAM35A). Cells were exposed to mitomycin C (MMC, 100Â ng/ml) for 18Â h or mockâexposed. Following sequential immunoprecipitation with FLAG and HA antibody beads, proteins were separated and identified by mass spectrometry (FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>B). DNA repair proteins associating with FAM35A included REV7, RIF1, BLM, and TOP3A (TableÂ <xref rid="embj201899543-tbl-0002" ref-type="table-wrap">2</xref>), with relatively more RIF1 peptides and 53BP1 identified following MMC exposure (TableÂ <xref rid="embj201899543-tbl-0003" ref-type="table-wrap">3</xref>).</p>
        <table-wrap id="embj201899543-tbl-0002" xml:lang="en" orientation="portrait" position="float">
          <label>Table 2</label>
          <caption>
            <p>DNA repair proteins identified in the FAM35A complex</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Protein</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Accession number (UniProtKB)</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Molecular weight</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Spectral counts</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Unique peptides</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">FAM35A</td>
                <td align="left" rowspan="1" colspan="1">Q86V20â2|FA35A_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">92Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">170</td>
                <td align="char" char="." rowspan="1" colspan="1">37</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">REV7</td>
                <td align="left" rowspan="1" colspan="1">Q9UI95|MD2L2_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">24Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">2</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">RIF1</td>
                <td align="left" rowspan="1" colspan="1">Q5UIP0â2|RIF1_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">272Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">BLM</td>
                <td align="left" rowspan="1" colspan="1">H0YNU5|H0YNU5_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">144Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">TOP3A</td>
                <td align="left" rowspan="1" colspan="1">Q13472|TOP3A_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">112Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">5</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn fn-type="equal" id="embj201899543-note-0002">
              <p>Proteins immunoprecipitating with exogenously expressed FAM35A were separated on a denaturing polyacrylamide gel, and proteins from gel sections of approximately equal size were identified by LCâMS/MS. TableÂ shows the significant DNA repairârelated proteins that were detected.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <table-wrap id="embj201899543-tbl-0003" xml:lang="en" orientation="portrait" position="float">
          <label>Table 3</label>
          <caption>
            <p>DNA repair proteins identified in the FAM35A complex after MMC exposure</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Protein</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Accession number (UniProtKB)</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Molecular weight</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Spectral counts</th>
                <th align="center" valign="top" rowspan="1" colspan="1">Unique peptides</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">FAM35A</td>
                <td align="left" rowspan="1" colspan="1">Q86V20â2|FA35A_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">92Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">623</td>
                <td align="char" char="." rowspan="1" colspan="1">69</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">RIF1</td>
                <td align="left" rowspan="1" colspan="1">Q5UIP0â2|RIF1_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">272Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">315</td>
                <td align="char" char="." rowspan="1" colspan="1">112</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">REV7</td>
                <td align="left" rowspan="1" colspan="1">Q9UI95|MD2L2_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">24Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">21</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Ku80</td>
                <td align="left" rowspan="1" colspan="1">P13010|XRCC5_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">83Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">BLM</td>
                <td align="left" rowspan="1" colspan="1">H0YNU5|H0YNU5_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">144Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">6</td>
                <td align="char" char="." rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">53BP1</td>
                <td align="left" rowspan="1" colspan="1">Q12888â2|TP53B_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">214Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
                <td align="char" char="." rowspan="1" colspan="1">3</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Ku70</td>
                <td align="left" rowspan="1" colspan="1">P12956|XRCC6_HUMAN</td>
                <td align="char" char="." rowspan="1" colspan="1">70Â kDa</td>
                <td align="char" char="." rowspan="1" colspan="1">11</td>
                <td align="char" char="." rowspan="1" colspan="1">7</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn fn-type="equal" id="embj201899543-note-0003">
              <p>Proteins from gel sections were identified by LCâMS/MS. The gel sections were approximately equal size with the exception of a wider segment for the FAM35A bait. The top associated hits were RIF1 and REV7. All other known DNA repairârelated proteins that were detected are shown. Ku70 and Ku80 may be nonâsignificant associations as they are found frequently in control experiments with agarose supports and FlagâHis tags (<ext-link ext-link-type="uri" xlink:href="http://www.crapome.org">http://www.crapome.org</ext-link>), but they are included here as they were not detected with significance in the complex from nonâdamaged cells (TableÂ <xref rid="embj201899543-tbl-0002" ref-type="table-wrap">2</xref>).</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
        <p>Although REV7 is known to cooperate functionally with 53BP1 to limit resection at DNA breaks, REV7 was not detected in 53BP1 immunocomplexes, and it is unknown how REV7 connects with 53BP1 <italic>inÂ vivo</italic> (Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>). To verify an association of FAM35A with 53BP1 and the additional DNA end resection control factor RIF1, FHâFAM35A was coâtransfected with GFPâRIF1 or GFPâ53BP1 and expressed in 293T cells. All proteins were expressed at the predicted molecular weights (FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>C, âinputâ lanes). Following immunoprecipitation with GFP antibody beads, FAM35A coâimmunoprecipitated with recombinant RIF1 or 53BP1 (but not with the control vector, FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>C). These interactions suggest that FAM35A may functionally bridge 53BP1 and REV7 in human cells, directly or via interactions with other proteins.</p>
      </sec>
      <sec id="embj201899543-sec-0004">
        <title>FAM35A is an OBâfold protein that changes localization following DNA damage</title>
        <p>We found <italic>FAM35A</italic> orthologs are present in vertebrate genomes, but not in invertebrates or plants. Multiple protein isoforms arising from alternative splicing are annotated in genomics databases for human (UniProt accession number Q86V20) and mouse FAM35A. Isoforms 1 and 2 are the most common, encoding 904 and 835 amino acid proteins, respectively. They arise by differential splicing of one inâframe exon (FigÂ <xref rid="embj201899543-fig-0002" ref-type="fig">2</xref>A). Both mRNA isoforms of FAM35A are ubiquitously expressed in different cell and tissue types (<ext-link ext-link-type="uri" xlink:href="http://www.gtexportal.org">http://www.gtexportal.org</ext-link>).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>
<styled-content style="fixed-case">FAM</styled-content>35A is an <styled-content style="fixed-case">OB</styled-content>âfold protein with an Nâterminal disordered region</title>
            <p>
<list list-type="alpha-upper" id="embj201899543-list-0003"><list-item><p>Domain schematic of human FAM35A derived from sequence prediction modeling. An Nâterminal disordered region includes postâtranslational modification sites. Locations of the three OBâfold domains A, B, and C are shown, with a Znâribbon containing conserved Cys residues. One exon is absent in isoform 2 compared to isoform 1, deleting 69 aa from OB domain B.</p></list-item><list-item><p>Multiâspecies alignment of a segment of FAM35A protein in the predicted Znâribbon. The four Znâcoordinating Cys residues (CxxC, CxxC), homologous to those in human RPA1, are evolutionarily conserved.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="EMBJ-37-e99543-g004"/>
        </fig>
        <p>BLAST searches for sequence homologs did not reveal significant primary sequence similarity to gene products other than FAM35A. We therefore analyzed the FAM35A protein sequence using structure prediction servers based on PSIâBLAST. The Nâterminal half of the protein is predicted to be disordered up until about residue 420 (FigÂ <xref rid="embj201899543-fig-0002" ref-type="fig">2</xref>A), and this region is likely to interact with other proteins, as found commonly for disordered regions of polypeptides (ReceveurâBrechot <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0038" ref-type="ref">2006</xref>). The Nâterminal region contains previously identified postâtranslational modification sites, including a conserved ubiquitin modification (Kim <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0024" ref-type="ref">2011</xref>) and a conserved SQ site (Matsuoka <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0032" ref-type="ref">2007</xref>) in which residue S339 is phosphorylated after exposure to ionizing radiation or UV radiation (Matsuoka <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0032" ref-type="ref">2007</xref>). With high significance, the Câterminal portion of FAM35A is predicted to contain three OBâfold domains structurally homologous to those in the 70Â kDa subunit (RPA1) of the singleâstranded DNAâbinding protein RPA (FigsÂ <xref rid="embj201899543-fig-0002" ref-type="fig">2</xref>A and <xref rid="embj201899543-fig-0001ev" ref-type="fig">EV1</xref>). The three OB folds are similar to DNAâbinding domain folds A, B, and C of RPA (Bochkareva <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0002" ref-type="ref">2002</xref>; Fan &amp; Pavletich, <xref rid="embj201899543-bib-0010" ref-type="ref">2012</xref>). OBâfold domain C is predicted to include four conserved cysteine residues (FigÂ <xref rid="embj201899543-fig-0002" ref-type="fig">2</xref>B) at the core of a zincâbinding ribbon, homologous to a loop in the same position in RPA (FigÂ <xref rid="embj201899543-fig-0002ev" ref-type="fig">EV2</xref>). Together, the OB folds and Znâribbon form the elements of DNAâbinding and orientationâenabling RPA1 to simultaneously bind to protein partners and to singleâstranded DNA in an 8â10Â nt binding mode (Lin <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0028" ref-type="ref">1998</xref>; Bochkareva <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0002" ref-type="ref">2002</xref>; Arunkumar <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0001" ref-type="ref">2003</xref>). The region including the 4âCys Znâribbon identifies the domain of unknown function (PF15793) that is conserved in FAM35A homologs as annotated by the Pfam database. Câterminal helices are predicted present following OB domains A and B, in positions corresponding to helices involved in multimerization of the OB folds in RPA subunits (Bochkareva <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0002" ref-type="ref">2002</xref>; Fan &amp; Pavletich, <xref rid="embj201899543-bib-0010" ref-type="ref">2012</xref>; FigÂ <xref rid="embj201899543-fig-0002ev" ref-type="fig">EV2</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201899543-fig-0001ev" orientation="portrait" position="float">
          <label>Figure EV1</label>
          <caption>
            <title>Partial model of the <styled-content style="fixed-case">OB</styled-content>âfold domains of <styled-content style="fixed-case">FAM</styled-content>35A</title>
            <p>A view of a model generated by Phyre2 is shown for FAM35A isoform 1 residues 402â904, using template 4GOP (chain C, the RPA 70Â kDa subunit from <italic>Ustilago maydis</italic>). TheÂ model includes OB folds with fiveâstranded beta barrels for OB domain A and OB domain B. The first three beta strands of OB domain C are modeled, with the Znâribbon that occurs in a loop between OB fold C beta strands 1 and 2 (FigÂ <xref rid="embj201899543-fig-0002ev" ref-type="fig">EV2</xref>). The Phyre2 coordinates were rendered in PyMOL using spectrum coloring.</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="EMBJ-37-e99543-g003"/>
        </fig>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201899543-fig-0002ev" orientation="portrait" position="float">
          <label>Figure EV2</label>
          <caption>
            <title>Secondary structure element assignment for the ordered region of human <styled-content style="fixed-case">FAM</styled-content>35A</title>
            <p>The secondary structure assignment is derived from the Phyre2 model of human FAM35A isoform 1 (FigÂ <xref rid="embj201899543-fig-0001ev" ref-type="fig">EV1</xref>) and largely coincides with features in the three functional DNAâbinding domains (dbdA, B, and C) of RPA1 (PDB: 4GOP, 1FGU), with a few differences. In FAM35A, a Câterminal helix is predicted to be present at the end of both OBÂ foldsÂ A and B, unlike in RPA1 where this helix only follows OB domain B. Beta strands 4 and 5 of OB domain C were not modeled by Phyre2 but candidate beta strandsÂ areÂ present in appropriate positions, as noted. The exon that is absent in FAM35A isoform 2 results in 69 fewer residues (red box), deleting structural elements of OB domain B.</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="EMBJ-37-e99543-g005"/>
        </fig>
        <p>We constructed a human U2OS cell line stably expressing GFPâFAM35A. Cells were exposed to MMC (100Â ng/ml, 24Â h) or mockâexposed and then fixed and stained with DAPI and antiâGFP. In cells exposed to DNAâdamaging agent, GFPâFAM35A was concentrated into foci in the nucleus (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>A), suggesting a direct involvement in DNA repair.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <title>
<styled-content style="fixed-case">FAM</styled-content>35A is a <styled-content style="fixed-case">DNA</styled-content> damage response gene</title>
            <p>
<list list-type="simple" id="embj201899543-list-0004"><list-item><label>A</label><p>GFPâFAM35A forms nuclear foci upon DNA damage. A U2OS cell line stably expressing GFPâFAM35A was exposed to MMC (100Â ng/ml, 24Â h) (right) or to mock treatment (left). The following day, cells were fixed and stained for DAPI and antiâGFP. Scale bars: 6Â Î¼m.</p></list-item><list-item><label>B</label><p>Two pseudogenes (<italic>FAM35DP</italic> and <italic>FAM35BP</italic>) with &gt;Â 98% identity to <italic>FAM35A</italic> are located on chromosome 10q22. Both <italic>FAM35DP</italic> and <italic>FAM35BP</italic> are present in genomes of apes and oldâworld monkeys, but not in other mammalian genomes. By inference, these pseudogenes arose by whole gene duplication in the common ancestor of the catarrhines about 25â30 million years ago. A third pseudogene (not shown) is <italic>FAM35CP,</italic> an inactive spliced product of reverse transcription (&gt;Â 95% identity) that was integrated into an intron of the galactosylceramidase (<italic>GALC</italic>) gene on chromosome 14q31.3. <italic>FAM35CP</italic> is present in apes but not oldâworld monkeys, indicating a more recent evolutionary origin.</p></list-item><list-item><label>C</label><p>Acute depletion of FAM35A causes hypersensitivity to several DNAâdamaging agents but not to olaparib. The survival of HEK293 cells, FAM35A acutely depleted and control, was monitored following exposure to MMC, etoposide, and olaparib. siControl (circle symbol, green line). siFAM35A (square symbol, blue line). siFANCD2 (triangle symbol, red line). siFANCA (triangle symbol, black line). siRNAâtreated cells were plated and exposed to indicate dose of agent for 48Â h. Cellular viability was measured 48Â h later. Data represent meanÂ Â±Â SEM. <italic>n</italic>Â =Â 3. *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05 and **<italic>P</italic>Â &lt;Â 0.01 by unpaired <italic>t</italic>âtest.</p></list-item><list-item><label>DâF</label><p>Quantification analysis of &gt;Â 5 nuclear Î³H2AX foci (D), &gt;Â 5 FANCD2 foci (E), and &gt;Â 5 RAD51 foci (F) in HEK293 cells acutely depleted for FAM35A. Cells with &gt;Â 5 foci/nucleus were counted after MMC (100Â ng/ml, 24Â h) or control treatment. Data shown are meansÂ Â±Â SE of more than 250 nuclei from two independent experiments. ns: not significant, **<italic>P</italic>Â &lt;Â 0.01 and ***<italic>P</italic>Â &lt;Â 0.001 by unpaired <italic>t</italic>âtest.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-13" xlink:href="EMBJ-37-e99543-g006"/>
        </fig>
      </sec>
      <sec id="embj201899543-sec-0005">
        <title>FAM35A depletion sensitizes cell lines to DNA damage</title>
        <p>The human <italic>FAM35A</italic> gene is located on chromosome 10q23.2. Three pseudogenes are also present in the human genome, two of them on 10q22 (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>B) with high (&gt;Â 98%) sequence identity to <italic>FAM35A</italic>. Precise nucleaseâmediated knockout of human <italic>FAM35A</italic> is therefore challenging, as simultaneous targeting of pseudogenes would likely cause chromosome rearrangements and deletion. siRNA was used to acutely deplete FAM35A from human HEK293 cells and investigate its role in DNA repair. FAM35Aâdepleted HEK293 cultures were hypersensitive to MMC and etoposide, with sensitivity comparable to that conferred by depletion of Fanconi anemia <italic>FANCA</italic> and <italic>FANCD2</italic> gene expression (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>C). In HEK293 cells, <italic>FAM35A</italic>âsiRNA did not sensitize to the PARP inhibitor olaparib (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>C), suggesting that homologous recombination repair is still active in the absence of FAM35A, as it is in cells with suppressed REV7 activity (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>).</p>
        <p>We investigated the impact of acute depletion of FAM35A on other markers of DNA damage responses in HEK293 cells. Cells with &gt;Â 5 Î³H2AX foci, &gt;Â 5 FANCD2 foci, or &gt;Â 5 RAD51 foci were quantified after MMC exposure (100Â ng/ml, 24Â h) and in control cells. MMC exposure induced cellular Î³H2AX foci as expected; there was no significant change in this pattern in cells depleted for FAM35A, indicating intact signaling leading to Î³H2AX formation (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>D). The Fanconi anemia signaling pathway (FANCD2 foci) was also functional in FAM35Aâdepleted cells, showing about 1.5âfold more foci after MMC exposure (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>E). RAD51 foci, a readout of homologous recombination pairing, were formed in FAM35Aâdefective cells, with a twofold elevated frequency in nonâdamaged cells (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>F).</p>
        <p>Depletion of REV7 reduces the efficiency of nonâhomologous endâjoining (NHEJ; Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>) by promoting resection that channels repair of DNA doubleâstrand breaks into homologous recombination and other pathways. Because of the association between FAM35A and the resection control factors REV7, RIF1, and 53BP1 (FigÂ <xref rid="embj201899543-fig-0001" ref-type="fig">1</xref>AâC), we investigated whether FAM35A depletion affects end joining, using a plasmid integration assay (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>). REV7, 53BP1, and RIF1 depletion decreased integration ratio in this assay. We confirmed efficient knockdown of <italic>FAM35A</italic> mRNA and protein in 293T cells using qPCR (FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>A) and immunoblot analysis (FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>B). The plasmid integration ratio decreased significantly after FAM35A depletion (FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>C), suggesting that FAM35A is involved in modulating doubleâstrand break repair pathway choice. Expression of FAM35A isoform 1 in 293T cells (FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>D) restored NHEJ to normal levels (FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>E). This is consistent with increased resection in the absence of FAM35A, causing NHEJ to be less effective, which may account for the increased sensitivity of FAM35Aâdepleted cells to MMC and etoposide.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <title>Suppression of <styled-content style="fixed-case">FAM</styled-content>35A reduces random <styled-content style="fixed-case">DNA</styled-content> integration by nonâhomologous endâjoining</title>
            <p>
<list list-type="simple" id="embj201899543-list-0005"><list-item><label>A, B</label><p>Depletion of endogenous FAM35A mRNA (A) and protein (B) from 293T cell lines carrying shRNA to FAM35A. Cell lysates were made from 293T cell lines stably depleted for FAM35A and controls. After electrophoretic transfer of proteins, the membrane was immunoblotted with antiâFAM35A or antiâÎ±âtubulin.</p></list-item><list-item><label>C</label><p>Plasmid integration assay. pDsRedâMonomer plasmid with antibiotic resistance (Hygromycin B) was linearized by restriction enzyme. The linearized plasmid was transfected into stably FAM35Aâdepleted 293T cell lines and control. Colonies were counted after antibiotic selection (Hygromycin B 300Â Î¼g/ml).</p></list-item><list-item><label>D</label><p>Expression of FAM35A isoform 1 (mouse) in human 293T cells with stable suppression of human FAM35A. The immunoblot of cell lysates used an antiâHA antibody to recognize epitopeâtagged mouse FAM35A.</p></list-item><list-item><label>E</label><p>Plasmid integration frequency is restored by expression of FAM35A in cells.</p></list-item></list>Data information: Data represent meanÂ Â±Â SEM. <italic>n</italic>Â =Â 4. *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, **<italic>P</italic>Â &lt;Â 0.01, ***<italic>P</italic>Â &lt;Â 0.001 and ****<italic>P</italic>Â &lt;Â 0.0001 by unpaired <italic>t</italic>âtest.<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-15" xlink:href="EMBJ-37-e99543-g008"/>
        </fig>
      </sec>
      <sec id="embj201899543-sec-0006">
        <title>FAM35A deficiency in BRCA1âdeficient cells and resistance to camptothecin and PARP inhibitors</title>
        <p>In BRCA1âmutant cells, REV7 depletion restores homologous recombination (HR) by restoring 5â² end resection (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>). We therefore hypothesized that FAM35A depletion from BRCA1âmutant cells would increase resistance to a DNA strandâbreaking agent. We engineered a BRCA1âmutant cell line (MDAâMBâ436) expressing FAM35A shRNA. Efficient knockdown was verified by qPCR (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>A). The FAM35Aâdepleted BRCA1âmutant cells and controls were assayed for sensitivity to camptothecin using a colonyâforming assay. FAM35A depletion from the BRCA1âmutant cell line significantly alleviated the sensitivity to camptothecin (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>A). Following exposure to ionizing radiation, a BRCA1âmutant cell line transfected with control siRNA did not form RAD51 foci, as expected (Johnson <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0022" ref-type="ref">2013</xref>). However, the BRCA1âmutant cells formed damageâdependent nuclear RAD51 foci following FAM35A depletion, suggesting that 5â² end resection was more active in the absence of FAM35A (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>B).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <title>
<styled-content style="fixed-case">FAM</styled-content>35A depletion/<styled-content style="fixed-case">KO</styled-content> in <styled-content style="fixed-case">BRCA</styled-content>1âdeficient cells enhances markers of homologous recombination</title>
            <p>
<list list-type="alpha-upper" id="embj201899543-list-0006"><list-item><p>Quantification of depletion of endogenous <italic>FAM35A</italic> mRNA and protein from 293T cell lines carrying shRNA to <italic>FAM35A</italic>. Colonyâforming assay: MDAâMBâ436 cells infected with nonâtargeting control or <italic>FAM35A</italic> shRNAs were treated for 24Â h with 20Â nM camptothecin, with medium changed and incubated until colonies appear; cells were then fixed and stained. Top row is untreated; second row is treated with camptothecin. Colony and cell numbers were counted. Bottom left is the number of cells 24Â h after seeding 1.5Â ÃÂ 10<sup>5</sup> cells. Bottom right is the colony count. Data represent meanÂ Â±Â SEM. <italic>n</italic>Â =Â 3. ns: not significant, *<italic>PÂ </italic>&lt;<italic>Â </italic>0.05, **<italic>P</italic>Â &lt;Â 0.01 and ***<italic>P</italic>Â &lt;Â 0.001 by unpaired <italic>t</italic>âtest.</p></list-item><list-item><p>FAM35Aâdepleted BRCA1âmutant cells form nuclear foci of RAD51 following DNA damage. MDAâMBâ436 cells infected with nonâtargeting control (second row) or <italic>FAM35A</italic> shRNAs (top row) were exposed to Xârays (10Â Gy). Cells were fixed after 6Â h and stained with DAPI and antiâRAD51. Scale bars: 10Â Î¼m.</p></list-item><list-item><p>Genes related to PARP inhibitor resistance in <italic>BRCA1</italic>âmutant cells and alterations of these genes in the HCC1937 cell line according to the CCLE.</p></list-item><list-item><p>Quantification of endogenous <italic>FAM35A</italic> mRNA expression. Endogenous <italic>FAM35A</italic> mRNA from HCC1937 (<italic>BRCA1</italic> mutant), HCC1937BL, and MDAâMBâ436 (<italic>BRCA1</italic> mutant) cell lines was quantified using qPCR. Data represent meanÂ Â±Â SEM. <italic>n</italic>Â =Â 3.</p></list-item><list-item><p>Detection of FAM35A exons 1 and 2 deletion in genomic DNA using PCR. Deletion of FAM35A exons 1 and 2 is confirmed in the HCC1937 cell line. In HCC1937 BL, endogenous FAM35A mRNA expression level was detectable. PCR primers for amplification of genomic DNA were designed in exon 1 (forward; primer 1) and exon 2 (reverse; primer 2). The predicted PCR product size is 1,794Â bp.</p></list-item></list>
</p>
            <p>
<named-content content-type="attribution">Source data are available online for this figure.</named-content>
</p>
          </caption>
          <graphic id="nlm-graphic-17" xlink:href="EMBJ-37-e99543-g009"/>
        </fig>
        <p>We investigated a further widely used cell line, HCC1937, which has a known inactivating mutation in BRCA1 (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>C). Multiple studies have noted that HCC1937 is anomalously resistant to PARP inhibitors in comparison with other BRCA1âmutant cell lines, for unknown reasons (Drew <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0008" ref-type="ref">2011</xref>; Lehmann <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0027" ref-type="ref">2011</xref>; Pierce <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0036" ref-type="ref">2013</xref>). In HCC1937, RAD51 foci (a marker of DNA end resection) are generated after DNA damage exposure (Zhang <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0053" ref-type="ref">2004</xref>; Hill <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0019" ref-type="ref">2014</xref>), and homologous recombination is partially active despite BRCA1 mutation (Zhang <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0053" ref-type="ref">2004</xref>). We found that <italic>FAM35A</italic> mRNA expression is absent in HCC1937 cells (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>D). FAM35A expression was present in HCC1937BL, an EBVâimmortalized lymphoblastoid cell line from the same patient (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>D). HCC1937BL is heterozygous for the BRCA1 mutation, indicating loss of heterozygosity for both FAM35A and BRCA1 in the HCC1937 mammary cancer patient.</p>
        <p>Genomic analysis of DNA from HCC1937 and MDAâMBâ436 cells showed that <italic>FAM35A</italic> DNA flanking exons 1 and 2 were not present in HCC1937 cells (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>E). This is consistent with a deep deletion at the <italic>FAM35A</italic> locus, notated by the Cancer Cell Line Encyclopedia (CCLE, Broad Institute) in HCC1937 cells (FigÂ <xref rid="embj201899543-fig-0003ev" ref-type="fig">EV3</xref>A). Reported genes related to PARP inhibitor resistance in BRCA1âmutant cellsÂ include <italic>53BP1</italic>,<italic> MAD2L2</italic>/<italic>REV7</italic>,<italic> RIF1</italic>,<italic> BLM</italic>,<italic> CHD4,</italic> and <italic>PTIP</italic> (Bunting <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0004" ref-type="ref">2010</xref>; Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>; Patel <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0035" ref-type="ref">2017</xref>). None are deleted in HCC1937 (FigÂ <xref rid="embj201899543-fig-0005" ref-type="fig">5</xref>C). DNA doubleâstrand break repair factors ATM (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>), NBS1 (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>), and RNF8 (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>) are also preserved in HCC1937 according to the CCLE.</p>
        <fig fig-type="Figure" xml:lang="en" specific-use="collapsible" id="embj201899543-fig-0003ev" orientation="portrait" position="float">
          <label>Figure EV3</label>
          <caption>
            <title>Potential <styled-content style="fixed-case">FAM</styled-content>35A alterations in human cancer cell lines</title>
            <p>
<list list-type="alpha-upper" id="embj201899543-list-0008"><list-item><p>Cell lines annotated in the Cancer Cell Line Encyclopedia with deep deletion of FAM35A. Data accessed from cBioPortal, February 2018. A region of chromosome 10q (red box) is expanded below to show calls for deep deletion (dark blue), shallow deletion (light blue), or amplification (red).</p></list-item><list-item><p>Quantification of endogenous FAM35A mRNA expression. Endogenous FAM35A mRNA from HCC1937 (<italic>BRCA1</italic> mutant), MDAâMBâ436 (<italic>BRCA1</italic> mutant), and LNCaP clone FGC cell lines was quantified using qPCR. Data represent mean Â± SEM. <italic>n</italic>Â =Â 3.</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-19" xlink:href="EMBJ-37-e99543-g007"/>
        </fig>
        <p>These data suggest an involvement of FAM35A in resection inhibition in parallel with REV7, 53BP1, and RIF1 (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>). Like 53BP1âdepleted BRCA1 mutants (Bunting <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0004" ref-type="ref">2010</xref>; Densham <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0007" ref-type="ref">2016</xref>), FAM35Aâdepleted BRCA1âmutant cells acquire camptothecin resistance. As HCC1937 cells can form 53BP1 foci and Mre11 foci (Zhang <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0053" ref-type="ref">2004</xref>) following DNA damage (Hill <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0019" ref-type="ref">2014</xref>), FAM35A appears to operate downstream of these factors and may serve as a link between 53BP1 and REV7. It is notable that the HCC1937 cell line relies on Pol Î¸âdependent alternative endâjoining for survival, perhaps unusually so for a BRCA1âdefective cell line (MateosâGomez <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0031" ref-type="ref">2015</xref>). A likely explanation is that the excessive DNA end resection activity arising from the FAM35A defect channels a substantial fraction of breaks into repair by DNA polymerase Î¸âmediated alternative endâjoining (Wyatt <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0051" ref-type="ref">2016</xref>).</p>
      </sec>
      <sec id="embj201899543-sec-0007">
        <title>FAM35A alterations and implications for cancers</title>
        <p>Currently, there are two major models to account for PARP inhibitor resistance in BRCA1âmutant cells: (i) 5â² resection through dysfunction of 53BP1, RIF1, or REV7 (Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>; Xu <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0052" ref-type="ref">2015</xref>) and (ii) deletion of recruiters (PTIP, CHD4, and PARP1) of enzymes that degrade newly synthesized DNA (Chaudhuri <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0006" ref-type="ref">2016</xref>). Our discovery of FAM35A deletion in HCC1937 alongside reported evidence suggests a plausible mechanism of FAM35Aâassociated PARP inhibitor resistance in line with the first model, via 5â² resection.</p>
        <p>We investigated the incidence of FAM35A alterations in cancer using cancer genomics databases. Mutations and copy number changes are found in FAM35A at a relatively low level (&lt;Â 5% of cases) in most cancer types. Strikingly, however, prostate cancer (PCa) data show deletion of <italic>FAM35A</italic> in a high fraction (6â13%) of cases (FigÂ <xref rid="embj201899543-fig-0006" ref-type="fig">6</xref>A). Prostate cancers are the only cancer type with this level of FAM35A deletion (for cancers with at least 40 cases per dataset). The <italic>PTEN</italic> gene, frequently deleted in PCa, is located on 10q23.2 about 0.5Â Mb distal of <italic>FAM35A</italic> (FigÂ <xref rid="embj201899543-fig-0003" ref-type="fig">3</xref>B). Some cases of FAM35A deletion are independent of <italic>PTEN</italic> deletion (FigÂ <xref rid="embj201899543-fig-0006" ref-type="fig">6</xref>B). A metaâanalysis of six datasets containing <italic>FAM35A</italic> mRNA expression data was performed to compare metastatic and primary tumors in prostate cancer. <italic>FAM35A</italic> mRNA expression is significantly reduced in metastatic prostate cancer (FigÂ <xref rid="embj201899543-fig-0006" ref-type="fig">6</xref>C). In prostate cancers, deletion of FAM35A is essentially exclusive from mutation or deletion of BRCA1. From the data presented here, tumors with FAM35A deletion might be predicted to be susceptible to treatment with DNA crossâlinking or doubleâstrand break inducing agents, but not to olaparib. Finally, we note that some other commonly used cancer cell lines harbor genetic deletion for FAM35A as annotated in the CCLE, although each must be confirmed experimentally. We found that prostate cancer cell line LNCaP clone FGC still expresses FAM35A mRNA (FigÂ <xref rid="embj201899543-fig-0003ev" ref-type="fig">EV3</xref>B).</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0006" orientation="portrait" position="float">
          <label>Figure 6</label>
          <caption>
            <title>
<styled-content style="fixed-case">FAM</styled-content>35A is a candidate tumor/metastasis suppressor gene in prostate cancer</title>
            <p>
<list list-type="alpha-upper" id="embj201899543-list-0007"><list-item><p>Prevalence of <italic>FAM35A</italic> deletion in prostate cancer (PCa) genomes analyzed via the cBioPortal. FAM35A gene is depleted in Ë6â13% of PCa, in the studies indicated.</p></list-item><list-item><p>FAM35A deletion is sometimes independent of alteration in PTEN. Comparison of <italic>FAM35A</italic> and <italic>PTEN</italic> alterations in PCa according to TCGA data (333 samples, Cancer Genome Atlas Network, <xref rid="embj201899543-bib-0005" ref-type="ref">2015</xref>) from the cBioPortal. Blue bar, homozygous deletion. Gray bar, no mutation. Green square, missense mutation. Black square, truncating mutation.</p></list-item><list-item><p>
<italic>FAM35A</italic> mRNA expression in primary vs. metastatic tumor according to Oncomine. The <italic>P</italic>âvalue for a gene is its <italic>P</italic>âvalue for the medianâranked analysis. The enumerated studies are Chandran Prostate (Chandran <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0100" ref-type="ref">2007</xref>), Grasso Prostate (Grasso <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0015" ref-type="ref">2012</xref>), Lapointe Prostate (Lapointe <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0025" ref-type="ref">2004</xref>), Taylor Prostate (Taylor <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0043" ref-type="ref">2010</xref>), Vanaja Prostate (Vanaja <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0046" ref-type="ref">2003</xref>), and Varambally Prostate (Varambally <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0047" ref-type="ref">2005</xref>).</p></list-item></list>
</p>
          </caption>
          <graphic id="nlm-graphic-21" xlink:href="EMBJ-37-e99543-g010"/>
        </fig>
        <p>The data presented here strongly implicate FAM35A in inhibition of DNA end resection following strand breakage (FigÂ <xref rid="embj201899543-fig-0007" ref-type="fig">7</xref>). In BRCA1âmutant cells, knockout of FAM35A allows recombination and/or alternative endâjoining repair pathways to be utilized more efficiently and helps explain the relative resistance to PARP inhibitors. Recently, a comprehensive survey of proteins associated with 53BP1 (Gupta <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0016" ref-type="ref">2018</xref>) uncovered REV7âbinding proteins including FAM35A (designated RINN2). siRNAâmediated suppression of BRCA1 in human U2OS cells increased their sensitivity to olaparib. When FAM35A/RINN2 was suppressed in these BRCA1âdefective cells, olaparib sensitivity was alleviated. This result is consistent with our interpretation outlined here, from analysis of FAM35A suppression in human cells and absence of expression in PARP inhibitorâresistant HCC1937 tumor cells. Based on theÂ protein interactions uncovered here and our prediction of singleâstranded DNAâbinding activity, a mechanism of action of FAM35A can be proposed whereby the protein interacts directly with singleâstranded DNA via its OBâfold domains. In this way, FAM35A may directly block activity of resection enzymes (BLMâDNA2, BLMâEXO1, and MRE11) or associate with BLM to prevent the interaction of BLM with DNA2 or EXO1.</p>
        <fig fig-type="Figure" xml:lang="en" id="embj201899543-fig-0007" orientation="portrait" position="float">
          <label>Figure 7</label>
          <caption>
            <title>Influence of <styled-content style="fixed-case">FAM</styled-content>35A on end resection</title>
            <p>During DNA replication, exposure to camptothecin or PARP inhibitors can block replication forks, sometimes producing a oneâended DSB. FAM35A, in concert with REV7, RIF1,Â 53BP1, and other proteins, is proposed to be involved in suppressing the resection at a DSB that produces 3â² singleâstranded DNA. Cells lacking BRCA1 are unable to counter the inhibition mediated by this protein complex. In FAM35Aâdefective cells, 5â² end resection can occur even in BRCA1 mutants, activating homologous recombination. This may be one mechanism of acquiring resistance to PARP inhibitor in BRCA1âmutant cells. However, excessive end resection can block the action of NHEJ.Â As an OBâfold protein, FAM35A may interact with singleâstranded DNA and then block nucleases or interactions with other proteins.</p>
          </caption>
          <graphic id="nlm-graphic-23" xlink:href="EMBJ-37-e99543-g011"/>
        </fig>
      </sec>
    </sec>
    <sec id="embj201899543-sec-0008">
      <title>Materials and Methods</title>
      <sec id="embj201899543-sec-0009">
        <title>Human cell cultures and transfections</title>
        <p>HEK293 (ATCC CRLâ1573), U2OS (ATCC HTBâ96), HEK293T (ATCC CRLâ11268), MDAâMBâ436 (ATCC HTBâ130), HCC1937 (ATCC CRLâ2336), and HCC1937 BL (ATCC CRLâ2337) cells were maintained in Dulbecco's modified Eagle's medium GlutaMAX<sup>TM</sup> (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum and penicillin/streptomycin in a 5% CO<sub>2</sub> incubator at 37Â°C. Human HeLa S3 cells were maintained in RPMI supplemented with 10% fetal bovine serum and penicillin/streptomycin in a 5% CO<sub>2</sub> incubator at 37Â°C. All cell lines were routinely checked for mycoplasma contamination using the MycoAlert detection kit (Lonza). Cell lines were validated by STR DNA fingerprinting by the Cell Line Identification Core of the MD Anderson Cancer Center. The STR profiles were compared to known ATCC fingerprints (ATCC.org), to the Cell Line Integrated Molecular Authentication (CLIMA) database version 0.1.200808 (<ext-link ext-link-type="uri" xlink:href="http://bioinformatics.hsanmartino.it/clima/">http://bioinformatics.hsanmartino.it/clima/</ext-link>; Romano <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0040" ref-type="ref">2009</xref>) and to the MD Anderson cell line fingerprint database.</p>
      </sec>
      <sec id="embj201899543-sec-0010">
        <title>siRNA transfection</title>
        <p>siRNA transfections were performed with Lipofectamine RNAiMAX (Life Technologies) according to manufacturer's instructions and as described previously (Takata <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0042" ref-type="ref">2013</xref>; Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0044" ref-type="ref">2013</xref>). Messenger RNA target sequences used for siRNAs were as follows: FANCAâspecific RNAs (5â²âAAGGGUCAAGAGGGAAAAAUAâ3â²) (Invitrogen), FANCD2âspecific RNAs (5â²âAAUGAACGCUCUUUAGCAGACAUGGâ3â²) (Invitrogen), FAM35Aâspecific RNA (5â²âAAGGAGUGGUUCUGAUUAAâ3â²) #6 (5â²âGUACUAAGAGUUGUUGAUU â3â²), #7 (5â²âGAACAGGAUCUACAAACAAâ3â²), and #8 (5â²âGCUCACAGUUCUCUGAAGAâ3â²) (Thermo Scientific). ONâTARGETplus NonâTargeting siRNAs were used as a negative control designated âsiControlâ (Thermo Scientific). The siRNAs were introduced into HEK293 cells.</p>
      </sec>
      <sec id="embj201899543-sec-0011">
        <title>Immunoprecipitation assay and protein identification</title>
        <p>Immunoprecipitation was performed as described (Takata <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0042" ref-type="ref">2013</xref>; Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0044" ref-type="ref">2013</xref>). Fortyâeight hours after transfection (for FHâFAM35A and GFP, GFPâ53BP1, or GFPâRIF1) in 293T cells, the cells were harvested. Each cell pellet was suspended with 300Â Î¼l of 0.5B (500Â mM KCl, 20Â mM TrisâHCl [pH 8.0], 5Â mM MgCl<sub>2</sub>, 10% glycerol, 1Â mM PMSF, 0.1% Tweenâ20, 10Â mM 2âmercaptoethanol), frozen in liquid nitrogen, thawed on ice, and sonicated. After centrifugation, 900Â Î¼l of 2B (40Â mM TrisâHCl [pH 8.0], 20% glycerol, 0.4Â mM EDTA, 0.2% Tweenâ20) was added to the supernatant and incubated with 10Â Î¼l of GFP agarose (MBL) for 4Â h at 4Â°C. The bound proteins were washed with 700Â Î¼l of 0.1B (100Â mM KCl, 20Â mM TrisâHCl [pH 8.0], 5Â mM MgCl<sub>2</sub>, 10% glycerol, 1Â mM PMSF, 0.1% Tweenâ20, 10Â mM 2âmercaptoethanol), three times and eluted with 30Â Î¼l of 2Ã SDS loading buffer (100Â mM TrisâHCl [pH 6.8], 4% SDS, 0.2% bromophenol blue, 20% glycerol, 200Â mM DTT). These samples were separated by polyacrylamide gel electrophoresis, transferred to a membrane, and detected with the indicated antibodies and ECL reagents (GE Healthcare). Protein identification was performed by LCâMS/MS mass spectrometry of gel slices as described previously (Takata <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0042" ref-type="ref">2013</xref>). Protein identifications were checked for agreement with the molecular mass predicted from the relevant gel slice. Protein identification established &gt;Â 99.9% protein probability assigned by the Protein ProphetÂ algorithm, with a minimum of two peptides at 95% peptide probability. Abundant proteins found commonly in immunoprecipitation experiments with these epitope tags and agarose were eliminated from consideration (Takata <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0042" ref-type="ref">2013</xref>). These included lamins, importins, chaperones, and ribosomal proteins.</p>
      </sec>
      <sec id="embj201899543-sec-0012">
        <title>Random plasmid integration assay</title>
        <p>The plasmid integration assay was performed as described (Lou <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0030" ref-type="ref">2004</xref>; Galanty <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0013" ref-type="ref">2012</xref>; Boersma <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0003" ref-type="ref">2015</xref>). Plasmid transfections were performed with Polyethylenimine 25kD linear from Polysciences (cat# 23966â2) as described (Lee <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0026" ref-type="ref">2014</xref>). Briefly, 24Â h after transfection (with linearized pDsRedâMonomerâHygâC1 (Clontech; #632495) with SmaI or XhoI) in FAM35Aâdepleted 293T cell lines and control cells, 1.5Â ÃÂ 10<sup>5</sup> cells were plated into replicate 10âcm dishes for Hygromycin B treatment and 5Â ÃÂ 10<sup>2</sup> cells were plated into replicate 10âcm dishes for plating efficiencies. The next day, Hygromycin B 300Â Î¼g/ml was added to the dish, and the cells were incubated until the appearance of colonies (10â14Â days). Cells were then fixed, stained, and counted. Statistical analysis was performed by unpaired <italic>t</italic>âtest (<italic>P</italic>Â &lt;Â 0.05).</p>
      </sec>
      <sec id="embj201899543-sec-0013">
        <title>shRNA vectors</title>
        <p>shRNA vectors were purchased from MD Anderson core facility: shFAM35A#1 (V2LH2S_221094), shFAM35A#2 (V2LH2S_277883), shFAM35A#3 (V3LH2S_359959), shFAM35A#4 (V3LH2S_359963), and shScramble (RHS4346).</p>
      </sec>
      <sec id="embj201899543-sec-0014">
        <title>Antibodies</title>
        <p>Antibodies purchased from SigmaâAldrich, with dilutions for immunoblotting, were as follows: F3165, monoclonal antiâFLAG 1:10,000; T5168, monoclonal antiâÎ± tubulin 1:8,000; A0168 HRP (horseradish peroxidase)âconjugated antiâmouse IgG 1:10,000, A0545 HRPâconjugated antiârabbit IgG 1:10,000; HPA036582, polyclonal antiâFAM35A 1:200. D153â8 agaroseâconjugated antiâGFP (RQ2) was purchased from MBL International Corporation. From Clontech, polyclonal antiâGFP antibody 632592 was used at 1:200 (for immunostaining); monoclonal antiâGFP 632381, 1:3,000. AntiâRAD51 antibody (B01P, 1:2,000) was purchased from Abnova. Goat antiâmouse IgG (H+L) secondary antibody, Alexa Fluor<sup>Â®</sup> 594 conjugate (Aâ11005) 1:2,000, goat antiârabbit IgG (H+L) secondary antibody, Alexa Fluor<sup>Â®</sup> 488 conjugate (Aâ11008) 1:2,000, and goat antiâmouse IgG (H+L) secondary antibody, Alexa Fluor<sup>Â®</sup> 488 conjugate (Aâ11001) 1:2,000 were purchased from Thermo Fisher. AntiâFANCD2 (EPR2302, 1:2,000 dilution) was purchased from GeneTex, Inc. From Cell Signaling Technology, monoclonal antiâHA (C29F4) was used at 1:1,000.</p>
      </sec>
      <sec id="embj201899543-sec-0015">
        <title>DNA constructs</title>
        <p>Human <italic>FAM35A</italic> cDNA (Clone ID: 6146593) was obtained from Thermo Scientific. Isoform 2 cDNA was PCR amplified from FAM35A cDNA as a XhoIâNotI fragment with 5â²FAM35A (XhoI) primer (5â²â CCGCTCGAGATGAGTGGAGGATCTCAAGTCCAC) and 3â²FAM35A (NotI) primer (5â²âTAAAAGCGGCCGCTCAGAGACGGGCATTGGCTCCATGC) to clone into pETDuetâ1 and pRSFDuetâ1 (Novagen). Fullâlength REV7 cDNA was cloned into pETDuetâ1 (Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0045" ref-type="ref">2015</xref>). The XhoIâNotI fragments from FAM35A and REV7 were inserted into pOZN and pOZC (Nakatani &amp; Ogryzko, <xref rid="embj201899543-bib-0034" ref-type="ref">2003</xref>; kindly provided by Hank Heng Qi, Children's Hospital, Boston) and pCDHâFH (Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0045" ref-type="ref">2015</xref>). FlagâHAâmouse FAM35A isoform 1 expression vector was PCR amplified from FAM35A cDNA as a XhoIâNotI fragment with 5â²mFAM35A (XhoI) primer (5â²âCCGCTCGAGATGAGTCAAGGATCACAAGTTCAC) and 3â²mFAM35A (NotI) primer (5â²âTAAAAGCGGCCGCTCACTCCTTCCCAGGAATGCCTCC) to clone into pCDHâFH. After construction, expression vectors were confirmed by DNA sequencing. pDESTpcDNA5âFRT/TOâeGFPâRif1 and pcDNA5âFRT/TOâeGFPâ53BP1 were gifts from Daniel Durocher (Addgene plasmid # 52506 and # 60813, respectively; EscribanoâDiaz <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0009" ref-type="ref">2013</xref>; FradetâTurcotte <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0012" ref-type="ref">2013</xref>).</p>
      </sec>
      <sec id="embj201899543-sec-0016">
        <title>DNA damage sensitivity in FAM35Aâdepleted cell lines</title>
        <p>To analyze sensitivity to chemical DNAâdamaging agents, HEK293 were plated into white 96âwell plates (1,250Â cells/well). The next day, various concentrations of MMC, etoposide, and olaparib were added to the wells, and the cells were incubated for 48Â h. The cells were lysed and a reagent that luminesces in the presence of ATP was added (ATPLite One Step, Perkin Elmer). Luminescence was measured using a plate reader (Biotek Synergy II) and normalized to undamaged control. For the clonogenic assay, 1.5Â ÃÂ 10<sup>5</sup> cells were plated in 10âmm culture plates and incubated for 24Â h prior to DNA damage induction. Groups of plates were exposed to camptothecin (20Â nM). After 24Â h, medium was changed, and cells were incubated until the appearance of colonies (14â21Â days). Cells were then fixed, stained, and counted. Statistical analysis was performed by unpaired <italic>t</italic>âtest (<italic>P</italic>Â &lt;Â 0.05).</p>
      </sec>
      <sec id="embj201899543-sec-0017">
        <title>Foci analysis by microscopy</title>
        <p>Immunofluorescence photography used a Leica DMI6000B microscope as described previously (Takata <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0042" ref-type="ref">2013</xref>). U2OS cells stably expressing GFPâFAM35A were plated into an 8âwell chamber slide. Cells were exposed to MMC (100Â ng/ml, 24Â h) and were fixed the following day with paraformaldehyde and stained for DAPI and GFP (Tomida <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0044" ref-type="ref">2013</xref>). To measure the formation of DNA doubleâstrand breaks and downstream signaling, FAM35A acutely depleted and control HEK293 cells were plated in 8âwell chamber slides, treated with MMC (100Â ng/ml 24Â h), fixed with paraformaldehyde, and stained for DAPI and Î³H2AX or FANCD2 (Song <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0041" ref-type="ref">2010</xref>). Î³H2AX or FANCD2 foci numbers were counted and plotted. FAM35Aâdepleted BRCA1âmutant cells were plated in 4âwell chamber slides and exposed to Xârays the following day (10Â Gy, 2Â Gy/min, 160Â kV peak energy with a Rad Source 2000 irradiator, Suwanee, GA). Six hours later, cells were fixed with paraformaldehyde and stained for DAPI and RAD51 (Song <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0041" ref-type="ref">2010</xref>; Johnson <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0022" ref-type="ref">2013</xref>).</p>
      </sec>
      <sec id="embj201899543-sec-0018">
        <title>Genomic PCR</title>
        <p>Total DNA was isolated from HCC1937 and MDAâMBâ436 cells using a DNeasy Blood &amp; Tissue Kit (Qiagen) following the manufacturer's protocol. Total DNA (400Â ng) was used as a template for genomic DNA amplification of FAM35A exons 1 and 2 by PCR with primer 1 (5â²âACGGGCGGCCGGATTTGCCCGGAGG) and primer 2 (5â²âCTTAATCTTTTGACCATCAAGG). Control primers were REV3LâF (5â²âACAGCTTCAGAGGAAAGCCA) and REV3LâR (5â²âGTTACCGATCGTGTCCGTTT).</p>
      </sec>
      <sec id="embj201899543-sec-0019">
        <title>Quantitative PCR (qPCR) assay</title>
        <p>Total RNA was extracted using an RNeasy Mini Kit (Qiagen) following the manufacturer's protocol including onâcolumn DNase treatment. Total RNA (1Â Î¼g) was used as a template to synthesize cDNA with the HighâCapacity cDNA Reverse Transcription Kit (Thermo Fisher). qPCR was then performed on the ABI 7900HT Fast RealâTime PCR System (Applied Biosystems). TaqMan primers and the probe sets for <italic>hFAM35A</italic> were purchased from Thermo Fisher (assay ID Hs04189036_m1). The absolute quantity (AQ) of transcripts for <italic>hFAM35A</italic> was determined using the generated standard curves. Standard curves for each gene were determined using the plasmid pRSFDuetâ1 carrying one of <italic>hFAM35A</italic>. Each reaction was performed in triplicate.</p>
      </sec>
      <sec id="embj201899543-sec-0020">
        <title>Bioinformatics</title>
        <p>Analysis of predicted protein disorder used the DisEMBL (<ext-link ext-link-type="uri" xlink:href="http://dis.embl.de">http://dis.embl.de</ext-link>), Pondr (<ext-link ext-link-type="uri" xlink:href="http://pondr.com">http://pondr.com</ext-link>), and Phyre2 webâbased servers (Kelley <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0023" ref-type="ref">2015</xref>). Protein structure prediction was crossâchecked using multiple tools. Several structure prediction servers identified models corresponding to OB domain A. ModWeb (<ext-link ext-link-type="uri" xlink:href="https://modbase.compbio.ucsf.edu">https://modbase.compbio.ucsf.edu</ext-link>) predicts high confidence similarity (sequence identify 18%) of FAM35A residues corresponding to OB fold A with PDB code 2K50 (<italic>Methanobacterium thermoautotrophicum</italic> RPA protein OB fold) and other with other RPA models. SwissModel (<ext-link ext-link-type="uri" xlink:href="https://swissmodel.expasy.org/">https://swissmodel.expasy.org/</ext-link>) identified homology of FAM35A 904 aa isoform residues 583â735 (OB fold B) with human RPA1 OBâfold PDB code 1FGU. When the Câterminal 480 amino acids of FAM35A were submitted to Phyre2 for structure prediction, the highest scoring template was PDB code 4GOP (71% coverage, 99.4% confidence). OB folds A, B, and the first part of OB folds C were modeled from 4GOP. The OB fold C model and is consistent with a partial OB fold predicted for FAM35A residues 736â836, PDB code 3U50.</p>
        <p>Cancer genome data and Cancer Cell Line Encyclopedia data were accessed from the cBioPortal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>) for Cancer Genomics (Gao <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0014" ref-type="ref">2013</xref>). Oncomine (Rhodes <italic>etÂ al</italic>, <xref rid="embj201899543-bib-0039" ref-type="ref">2007</xref>) (<ext-link ext-link-type="uri" xlink:href="http://www.oncomine.com">http://www.oncomine.com</ext-link>) was used for metaâanalysis of six datasets containing FAM35A mRNA expression data (all six datasets are microarrays) with comparisons between metastatic and primary tumor in prostate cancer. Total patient numbers and detailed information regarding published datasets and associated publications are indicated in FigÂ <xref rid="embj201899543-fig-0004" ref-type="fig">4</xref>B.</p>
      </sec>
    </sec>
    <sec id="embj201899543-sec-0022">
      <title>Author contributions</title>
      <p>JT and KâiT conceived and designed the experiments. JT and RDW designed the research. JT, SB, and MDP performed research. JT, KâiT, HâPC, DGT, and RDW analyzed data. JT and RDW wrote the manuscript.</p>
    </sec>
    <sec id="embj201899543-sec-0023">
      <title>Conflict of interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data"/>
      <supplementary-material content-type="local-data" id="embj201899543-sup-0001">
        <caption>
          <p>Expanded View Figures PDF</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Review process File</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s006.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201899543-supp-data-0001">
        <caption>
          <p>Source Data for FigureÂ 1</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s002.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201899543-supp-data-0002">
        <caption>
          <p>Source Data for FigureÂ 3</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s003.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201899543-supp-data-0003">
        <caption>
          <p>Source Data for FigureÂ 4</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s004.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="embj201899543-supp-data-0004">
        <caption>
          <p>Source Data for FigureÂ 5</p>
        </caption>
        <media xlink:href="EMBJ-37-e99543-s005.tif">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="embj201899543-sec-0021">
      <title>Acknowledgments</title>
      <p>We thank Edmund O'Brien, Sara K. Martin, Megan Lowery, and Karen Boulware for assistance with experiments, Mary Walker for editorial help, Dr. Stefan Arold for initial OBâfold structural predictions in 2012, and Dr. Sylvie DoubliÃ© for PONDR disorder predictions and discussion. This research was supported by National Institutes of Health (NIH) grants CA132840, CA097175, CA193124 and the Grady F. Saunders Ph.D. Distinguished Research Professorship (to RDW), grant RP130297 from the Cancer Prevention and Research Institute of Texas (to RDW), and National Institutes of Health (NIH) grants CA212556 (to JT), and The University of Texas MD Anderson Cancer Center Institutional Research Grant and Center for Radiation Oncology Research (to KT). We also acknowledge funding from CPRIT Core Facility Support grant RP120348 and RP170002 and NIH Cancer Center Support Grant P30âCA016672 (University of Texas M. D. Anderson Cancer Center) and CPRIT grant RP110782 (to M.D.P.).</p>
    </ack>
    <ref-list content-type="cited-references" id="embj201899543-bibl-0001">
      <title>References</title>
      <ref id="embj201899543-bib-0001">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0001">
<string-name>
<surname>Arunkumar</surname>
<given-names>AI</given-names>
</string-name>, <string-name>
<surname>Stauffer</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Bochkareva</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bochkarev</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chazin</surname>
<given-names>WJ</given-names>
</string-name> (<year>2003</year>) <article-title>Independent and coordinated functions of replication protein A tandem high affinity singleâstranded DNA binding domains</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>278</volume>: <fpage>41077</fpage>â<lpage>41082</lpage>
<pub-id pub-id-type="pmid">12881520</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0002">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0002">
<string-name>
<surname>Bochkareva</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Korolev</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>LeesâMiller</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Bochkarev</surname>
<given-names>A</given-names>
</string-name> (<year>2002</year>) <article-title>Structure of the RPA trimerization core and its role in the multistep DNAâbinding mechanism of RPA</article-title>. <source xml:lang="en">EMBO J</source>
<volume>21</volume>: <fpage>1855</fpage>â<lpage>1863</lpage>
<pub-id pub-id-type="pmid">11927569</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0003">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0003">
<string-name>
<surname>Boersma</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Moatti</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>SeguraâBayona</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peuscher</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>van der Torre</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wevers</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Orthwein</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Durocher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jacobs</surname>
<given-names>JJ</given-names>
</string-name> (<year>2015</year>) <article-title>MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5â² end resection</article-title>. <source xml:lang="en">Nature</source>
<volume>521</volume>: <fpage>537</fpage>â<lpage>540</lpage>
<pub-id pub-id-type="pmid">25799990</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0004">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0004">
<string-name>
<surname>Bunting</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Callen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>HT</given-names>
</string-name>, <string-name>
<surname>Polato</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gunn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Bothmer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feldhahn</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>FernandezâCapetillo</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>CX</given-names>
</string-name>, <string-name>
<surname>Finkel</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nussenzweig</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stark</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Nussenzweig</surname>
<given-names>A</given-names>
</string-name> (<year>2010</year>) <article-title>53BP1 inhibits homologous recombination in Brca1âdeficient cells by blocking resection of DNA breaks</article-title>. <source xml:lang="en">Cell</source>
<volume>141</volume>: <fpage>243</fpage>â<lpage>254</lpage>
<pub-id pub-id-type="pmid">20362325</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0005">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0005">
<collab collab-type="authors">Cancer Genome Atlas Network</collab>
(<year>2015</year>) <article-title>The molecular taxonomy of primary prostate cancer</article-title>. <source xml:lang="en">Cell</source>
<volume>163</volume>: <fpage>1011</fpage>â<lpage>1025</lpage>
<pub-id pub-id-type="pmid">26544944</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0100">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0100">
<string-name>
<surname>Chandran</surname>
<given-names>UR</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dhir</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bisceglia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>LyonsâWeiler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Michalopoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Becich</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Monzon</surname>
<given-names>FA</given-names>
</string-name> (<year>2007</year>) <article-title>Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in theÂ metastatic process</article-title>. <source xml:lang="en">BMC Cancer</source>
<volume>7</volume>: <fpage>64</fpage>
<pub-id pub-id-type="pmid">17430594</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0006">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0006">
<string-name>
<surname>Chaudhuri</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Callen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Gogola</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Duarte</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lafarga</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Calvo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Panzarino</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>John</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Day</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Crespo</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Starnes</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>de Ruiter</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Daniel</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Konstantinopoulos</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Cortez</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cantor</surname>
<given-names>SB</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2016</year>) <article-title>Replication fork stability confers chemoresistance in BRCAâdeficient cells</article-title>. <source xml:lang="en">Nature</source>
<volume>535</volume>: <fpage>382</fpage>â<lpage>387</lpage>
<pub-id pub-id-type="pmid">27443740</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0007">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0007">
<string-name>
<surname>Densham</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Garvin</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Strachan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Baldock</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>DazaâMartin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fletcher</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>BlairâReid</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Beesley</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Johal</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Neely</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Keep</surname>
<given-names>NH</given-names>
</string-name>, <string-name>
<surname>Watts</surname>
<given-names>FZ</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>JR</given-names>
</string-name> (<year>2016</year>) <article-title>Human BRCA1âBARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection</article-title>. <source xml:lang="en">Nat Struct Mol Biol</source>
<volume>23</volume>: <fpage>647</fpage>â<lpage>655</lpage>
<pub-id pub-id-type="pmid">27239795</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0008">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0008">
<string-name>
<surname>Drew</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mulligan</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Vong</surname>
<given-names>WT</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Kahn</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kyle</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mukhopadhyay</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Los</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hostomsky</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Plummer</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Edmondson</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Curtin</surname>
<given-names>NJ</given-names>
</string-name> (<year>2011</year>) <article-title>Therapeutic potential of poly(ADPâribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2</article-title>. <source xml:lang="en">J Natl Cancer Inst</source>
<volume>103</volume>: <fpage>334</fpage>â<lpage>346</lpage>
<pub-id pub-id-type="pmid">21183737</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0009">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0009">
<string-name>
<surname>EscribanoâDiaz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Orthwein</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>FradetâTurcotte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Tkac</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Rosebrock</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Munro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Canny</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Durocher</surname>
<given-names>D</given-names>
</string-name> (<year>2013</year>) <article-title>A cell cycleâdependent regulatory circuit composed of 53BP1âRIF1 and BRCA1âCtIP controls DNA repair pathway choice</article-title>. <source xml:lang="en">Mol Cell</source>
<volume>49</volume>: <fpage>872</fpage>â<lpage>883</lpage>
<pub-id pub-id-type="pmid">23333306</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0010">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0010">
<string-name>
<surname>Fan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pavletich</surname>
<given-names>NP</given-names>
</string-name> (<year>2012</year>) <article-title>Structure and conformational change of a replication protein A heterotrimer bound to ssDNA</article-title>. <source xml:lang="en">Genes Dev</source>
<volume>26</volume>: <fpage>2337</fpage>â<lpage>2347</lpage>
<pub-id pub-id-type="pmid">23070815</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0011">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0011">
<string-name>
<surname>Fattah</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Hara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fattah</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Warrington</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Boothman</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name> (<year>2014</year>) <article-title>The transcription factor TFIIâI promotes DNA translesion synthesis and genomic stability</article-title>. <source xml:lang="en">PLoS Genet</source>
<volume>10</volume>: <fpage>e1004419</fpage>
<pub-id pub-id-type="pmid">24922507</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0012">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0012">
<string-name>
<surname>FradetâTurcotte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Canny</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>EscribanoâDiaz</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Orthwein</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Landry</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>KitevskiâLeBlanc</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Noordermeer</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Sicheri</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Durocher</surname>
<given-names>D</given-names>
</string-name> (<year>2013</year>) <article-title>53BP1 is a reader of the DNAâdamageâinduced H2A Lys 15 ubiquitin mark</article-title>. <source xml:lang="en">Nature</source>
<volume>499</volume>: <fpage>50</fpage>â<lpage>54</lpage>
<pub-id pub-id-type="pmid">23760478</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0013">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0013">
<string-name>
<surname>Galanty</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Belotserkovskaya</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Coates</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>SP</given-names>
</string-name> (<year>2012</year>) <article-title>RNF4, a SUMOâtargeted ubiquitin E3 ligase, promotes DNA doubleâstrand break repair</article-title>. <source xml:lang="en">Genes Dev</source>
<volume>26</volume>: <fpage>1179</fpage>â<lpage>1195</lpage>
<pub-id pub-id-type="pmid">22661229</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0014">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0014">
<string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Aksoy</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Dogrusoz</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Dresdner</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gross</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sumer</surname>
<given-names>SO</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jacobsen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sinha</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Larsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cerami</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sander</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>N</given-names>
</string-name> (<year>2013</year>) <article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>. <source xml:lang="en">Sci Signal</source>
<volume>6</volume>: <fpage>pl1</fpage>
<pub-id pub-id-type="pmid">23550210</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0015">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0015">
<string-name>
<surname>Grasso</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>YM</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Dhanasekaran</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Khan</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Quist</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Jing</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lonigro</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Brenner</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Asangani</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Ateeq</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Chun</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Siddiqui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sam</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Anstett</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mehra</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Prensner</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Palanisamy</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Ryslik</surname>
<given-names>GA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2012</year>) <article-title>The mutational landscape of lethal castrationâresistant prostate cancer</article-title>. <source xml:lang="en">Nature</source>
<volume>487</volume>: <fpage>239</fpage>â<lpage>243</lpage>
<pub-id pub-id-type="pmid">22722839</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0016">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0016">
<string-name>
<surname>Gupta</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Somyajit</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Narita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Maskey</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Stanlie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kremer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Typas</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lammers</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mailand</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nussenzweig</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lukas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Choudhary</surname>
<given-names>C</given-names>
</string-name> (<year>2018</year>) <article-title>DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity</article-title>. <source xml:lang="en">Cell</source>
<volume>73</volume>: <fpage>972</fpage>â<lpage>988</lpage>
</mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0017">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0017">
<string-name>
<surname>Hara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Murakumo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kogame</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Unzai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Akashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sato</surname>
<given-names>M</given-names>
</string-name> (<year>2010</year>) <article-title>Crystal structure of human REV7 in complex with a human REV3 fragment and structural implication of the interaction between DNA polymerase {Î¶} and REV1</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>285</volume>: <fpage>12299</fpage>â<lpage>12307</lpage>
<pub-id pub-id-type="pmid">20164194</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0018">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0018">
<string-name>
<surname>Hara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Taharazako</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mikami</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kikuchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hishiki</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yokoyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kanno</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>H</given-names>
</string-name> (<year>2017</year>) <article-title>Dynamic feature of mitotic arrest deficient 2âlike protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignmentâmaintaining phosphoprotein (CAMP)</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>292</volume>: <fpage>17658</fpage>â<lpage>17667</lpage>
<pub-id pub-id-type="pmid">28887307</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0019">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0019">
<string-name>
<surname>Hill</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Silver</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Livingston</surname>
<given-names>DM</given-names>
</string-name> (<year>2014</year>) <article-title>BRCA1 pathway function in basalâlike breast cancer cells</article-title>. <source xml:lang="en">Mol Cell Biol</source>
<volume>34</volume>: <fpage>3828</fpage>â<lpage>3842</lpage>
<pub-id pub-id-type="pmid">25092866</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0020">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0020">
<string-name>
<surname>Ikura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tashiro</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kakino</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shima</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jacob</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Amunugama</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yoder</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Izumi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kuraoka</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ikura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nishikubo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Muto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miyagawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fishel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Igarashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamiya</surname>
<given-names>K</given-names>
</string-name> (<year>2007</year>) <article-title>DNA damageâdependent acetylation and ubiquitination of H2AX enhances chromatin dynamics</article-title>. <source xml:lang="en">Mol Cell Biol</source>
<volume>27</volume>: <fpage>7028</fpage>â<lpage>7040</lpage>
<pub-id pub-id-type="pmid">17709392</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0021">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0021">
<string-name>
<surname>Itoh</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kanno</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Uchida</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Chiba</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sugino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yasui</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hirota</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</string-name> (<year>2011</year>) <article-title>CAMP (C13orf8, ZNF828) is a novel regulator of kinetochoreâmicrotubule attachment</article-title>. <source xml:lang="en">EMBO J</source>
<volume>30</volume>: <fpage>130</fpage>â<lpage>144</lpage>
<pub-id pub-id-type="pmid">21063390</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0022">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0022">
<string-name>
<surname>Johnson</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>YE</given-names>
</string-name>, <string-name>
<surname>Bernhardy</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Capelletti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sarosiek</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Moreau</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Chowdhury</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wickramanayake</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Harrell</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>D'Andrea</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Miron</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Swisher</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Shapiro</surname>
<given-names>GI</given-names>
</string-name> (<year>2013</year>) <article-title>Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>
<volume>110</volume>: <fpage>17041</fpage>â<lpage>17046</lpage>
<pub-id pub-id-type="pmid">24085845</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0023">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0023">
<string-name>
<surname>Kelley</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Mezulis</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yates</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Wass</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Sternberg</surname>
<given-names>MJE</given-names>
</string-name> (<year>2015</year>) <article-title>The Phyre2 web portal for protein modeling, prediction and analysis</article-title>. <source xml:lang="en">Nat Protoc</source>
<volume>10</volume>: <fpage>845</fpage>
<pub-id pub-id-type="pmid">25950237</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0024">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0024">
<string-name>
<surname>Kim</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Huttlin</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Possemato</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sowa</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Rad</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rush</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Comb</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Harper</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Gygi</surname>
<given-names>SP</given-names>
</string-name> (<year>2011</year>) <article-title>Systematic and quantitative assessment of the ubiquitinâmodified proteome</article-title>. <source xml:lang="en">Mol Cell</source>
<volume>44</volume>: <fpage>325</fpage>â<lpage>340</lpage>
<pub-id pub-id-type="pmid">21906983</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0025">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0025">
<string-name>
<surname>Lapointe</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Higgins</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>van de Rijn</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bair</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Montgomery</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Egevad</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rayford</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Bergerheim</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Ekman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>DeMarzo</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Tibshirani</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Botstein</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>PO</given-names>
</string-name>, <string-name>
<surname>Brooks</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Pollack</surname>
<given-names>JR</given-names>
</string-name> (<year>2004</year>) <article-title>Gene expression profiling identifies clinically relevant subtypes of prostate cancer</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>
<volume>101</volume>: <fpage>811</fpage>â<lpage>816</lpage>
<pub-id pub-id-type="pmid">14711987</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0026">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0026">
<string-name>
<surname>Lee</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Gregory</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>W</given-names>
</string-name> (<year>2014</year>) <article-title>Human Pol zeta purified with accessory subunits is active in translesion DNA synthesis and complements Pol eta in cisplatin bypass</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>
<volume>111</volume>: <fpage>2954</fpage>â<lpage>2959</lpage>
<pub-id pub-id-type="pmid">24449906</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0027">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0027">
<string-name>
<surname>Lehmann</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Sanders</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Chakravarthy</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Shyr</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Pietenpol</surname>
<given-names>JA</given-names>
</string-name> (<year>2011</year>) <article-title>Identification of human tripleânegative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>. <source xml:lang="en">J Clin Invest</source>
<volume>121</volume>: <fpage>2750</fpage>â<lpage>2767</lpage>
<pub-id pub-id-type="pmid">21633166</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0028">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0028">
<string-name>
<surname>Lin</surname>
<given-names>YâL</given-names>
</string-name>, <string-name>
<surname>Shivji</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kolodner</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Dutta</surname>
<given-names>A</given-names>
</string-name> (<year>1998</year>) <article-title>The evolutionarily conserved zinc finger motif in the largest subâunit of human RPA is required for DNA replication and mismatch repair but not for nucleotide excision repair</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>273</volume>: <fpage>1453</fpage>â<lpage>1461</lpage>
<pub-id pub-id-type="pmid">9430682</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0029">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0029">
<string-name>
<surname>Listovsky</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sale</surname>
<given-names>JE</given-names>
</string-name> (<year>2013</year>) <article-title>Sequestration of CDH1 by MAD2L2 prevents premature APC/C activation prior to anaphase onset</article-title>. <source xml:lang="en">J Cell Biol</source>
<volume>203</volume>: <fpage>87</fpage>â<lpage>100</lpage>
<pub-id pub-id-type="pmid">24100295</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0030">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0030">
<string-name>
<surname>Lou</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>BP</given-names>
</string-name>, <string-name>
<surname>Asaithamby</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>MinterâDykhouse</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name> (<year>2004</year>) <article-title>MDC1 regulates DNAâPK autophosphorylation in response to DNA damage</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>279</volume>: <fpage>46359</fpage>â<lpage>46362</lpage>
<pub-id pub-id-type="pmid">15377652</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0031">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0031">
<string-name>
<surname>MateosâGomez</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Gong</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nair</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>LazzeriniâDenchi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Sfeir</surname>
<given-names>A</given-names>
</string-name> (<year>2015</year>) <article-title>Mammalian polymerase Î¸ promotes alternative NHEJ and suppresses recombination</article-title>. <source xml:lang="en">Nature</source>
<volume>518</volume>: <fpage>254</fpage>â<lpage>257</lpage>
<pub-id pub-id-type="pmid">25642960</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0032">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0032">
<string-name>
<surname>Matsuoka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ballif</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Smogorzewska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McDonald</surname>
<given-names>ER</given-names>
<suffix>III</suffix>
</string-name>, <string-name>
<surname>Hurov</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bakalarski</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Solimini</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Lerenthal</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shiloh</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gygi</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Elledge</surname>
<given-names>SJ</given-names>
</string-name> (<year>2007</year>) <article-title>ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage</article-title>. <source xml:lang="en">Science</source>
<volume>316</volume>: <fpage>1160</fpage>â<lpage>1166</lpage>
<pub-id pub-id-type="pmid">17525332</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0033">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0033">
<string-name>
<surname>Medendorp</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>van Groningen</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Vreede</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hetterschijt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>van den Hurk</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>de Bruijn</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Brugmans</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>van Kessel</surname>
<given-names>AG</given-names>
</string-name> (<year>2009</year>) <article-title>The mitotic arrest deficient protein MAD2B interacts with the small GTPase RAN throughout the cell cycle</article-title>. <source xml:lang="en">PLoS One</source>
<volume>4</volume>: <fpage>e7020</fpage>
<pub-id pub-id-type="pmid">19753112</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0034">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0034">
<string-name>
<surname>Nakatani</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ogryzko</surname>
<given-names>V</given-names>
</string-name> (<year>2003</year>) <article-title>Immunoaffinity purification of mammalian protein complexes</article-title>. <source xml:lang="en">Methods Enzymol</source>
<volume>370</volume>: <fpage>430</fpage>â<lpage>444</lpage>
<pub-id pub-id-type="pmid">14712665</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0035">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0035">
<string-name>
<surname>Patel</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Misenko</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Her</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bunting</surname>
<given-names>SF</given-names>
</string-name> (<year>2017</year>) <article-title>BLM helicase regulates DNA repair by counteracting RAD51 loading at DNA doubleâstrand break sites</article-title>. <source xml:lang="en">J Cell Biol</source>
<volume>216</volume>: <fpage>3521</fpage>â<lpage>3534</lpage>
<pub-id pub-id-type="pmid">28912125</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0036">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0036">
<string-name>
<surname>Pierce</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McGowan</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Cotter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mullooly</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>O'Donovan</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Rani</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>O'Driscoll</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Crown</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Duffy</surname>
<given-names>MJ</given-names>
</string-name> (<year>2013</year>) <article-title>Comparative antiproliferative effects of iniparib and olaparib on a panel of tripleânegative and nonâtripleânegative breast cancer cell lines</article-title>. <source xml:lang="en">Cancer Biol Ther</source>
<volume>14</volume>: <fpage>537</fpage>â<lpage>545</lpage>
<pub-id pub-id-type="pmid">23760496</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0037">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0037">
<string-name>
<surname>Pirouz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pilarski</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kessel</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>A critical function of Mad2Â l2 in primordial germ cell development of mice</article-title>. <source xml:lang="en">PLoS Genet</source>
<volume>9</volume>: <fpage>e1003712</fpage>
<pub-id pub-id-type="pmid">24009519</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0038">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0038">
<string-name>
<surname>ReceveurâBrechot</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bourhis</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Uversky</surname>
<given-names>VN</given-names>
</string-name>, <string-name>
<surname>Canard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Longhi</surname>
<given-names>S</given-names>
</string-name> (<year>2006</year>) <article-title>Assessing protein disorder and induced folding</article-title>. <source xml:lang="en">Proteins</source>
<volume>62</volume>: <fpage>24</fpage>â<lpage>45</lpage>
<pub-id pub-id-type="pmid">16287116</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0039">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0039">
<string-name>
<surname>Rhodes</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>KalyanaâSundaram</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mahavisno</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Varambally</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Briggs</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>Barrette</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Anstet</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>KinceadâBeal</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kulkarni</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Varambally</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chinnaiyan</surname>
<given-names>AM</given-names>
</string-name> (<year>2007</year>) <article-title>Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles</article-title>. <source xml:lang="en">Neoplasia</source>
<volume>9</volume>: <fpage>166</fpage>â<lpage>180</lpage>
<pub-id pub-id-type="pmid">17356713</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0040">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0040">
<string-name>
<surname>Romano</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Manniello</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Aresu</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Armento</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cesaro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Parodi</surname>
<given-names>B</given-names>
</string-name> (<year>2009</year>) <article-title>Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>37</volume>: <fpage>D925</fpage>â<lpage>D932</lpage>
<pub-id pub-id-type="pmid">18927105</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0041">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0041">
<string-name>
<surname>Song</surname>
<given-names>IY</given-names>
</string-name>, <string-name>
<surname>Palle</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gurkar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tateishi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kupfer</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Vaziri</surname>
<given-names>C</given-names>
</string-name> (<year>2010</year>) <article-title>Rad18âmediated translesion synthesis of bulky DNA adducts is coupled to activation of the Fanconi anemia DNA repair pathway</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>285</volume>: <fpage>31525</fpage>â<lpage>31536</lpage>
<pub-id pub-id-type="pmid">20675655</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0042">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0042">
<string-name>
<surname>Takata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Reh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tomida</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Person</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name> (<year>2013</year>) <article-title>Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs</article-title>. <source xml:lang="en">Nat Commun</source>
<volume>4</volume>: <fpage>2338</fpage>
<pub-id pub-id-type="pmid">24005565</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0043">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0043">
<string-name>
<surname>Taylor</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Schultz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hieronymus</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Gopalan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Carver</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>VK</given-names>
</string-name>, <string-name>
<surname>Kaushik</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cerami</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Reva</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Antipin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mitsiades</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Landers</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dolgalev</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Major</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Socci</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Lash</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Heguy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eastham</surname>
<given-names>JA</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2010</year>) <article-title>Integrative genomic profiling of human prostate cancer</article-title>. <source xml:lang="en">Cancer Cell</source>
<volume>18</volume>: <fpage>11</fpage>â<lpage>22</lpage>
<pub-id pub-id-type="pmid">20579941</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0044">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0044">
<string-name>
<surname>Tomida</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Itaya</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shigechi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Unno</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Uchida</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ikura</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Masuda</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Adachi</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Meetei</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Maehara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamiya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matsuura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ikura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ishiai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takata</surname>
<given-names>M</given-names>
</string-name> (<year>2013</year>) <article-title>AÂ novel interplay between the Fanconi anemia core complex and ATRâATRIP kinase during DNA crossâlink repair</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>41</volume>: <fpage>6930</fpage>â<lpage>6941</lpage>
<pub-id pub-id-type="pmid">23723247</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0045">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0045">
<string-name>
<surname>Tomida</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Takata</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>Schibler</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Yousefzadeh</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bhetawal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dent</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name> (<year>2015</year>) <article-title>REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase zeta</article-title>. <source xml:lang="en">Nucleic Acids Res</source>
<volume>43</volume>: <fpage>1000</fpage>â<lpage>1011</lpage>
<pub-id pub-id-type="pmid">25567983</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0046">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0046">
<string-name>
<surname>Vanaja</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Cheville</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Iturria</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>CY</given-names>
</string-name> (<year>2003</year>) <article-title>Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression</article-title>. <source xml:lang="en">Cancer Res</source>
<volume>63</volume>: <fpage>3877</fpage>â<lpage>3882</lpage>
<pub-id pub-id-type="pmid">12873976</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0047">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0047">
<string-name>
<surname>Varambally</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Laxman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Rhodes</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Mehra</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Tomlins</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Chandran</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Monzon</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Becich</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Pienta</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rubin</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Chinnaiyan</surname>
<given-names>AM</given-names>
</string-name> (<year>2005</year>) <article-title>Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression</article-title>. <source xml:lang="en">Cancer Cell</source>
<volume>8</volume>: <fpage>393</fpage>â<lpage>406</lpage>
<pub-id pub-id-type="pmid">16286247</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0048">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0048">
<string-name>
<surname>Vermeulen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eberl</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Matarese</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Marks</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Denissov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Butter</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Olsen</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Hyman</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Stunnenberg</surname>
<given-names>HG</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>M</given-names>
</string-name> (<year>2010</year>) <article-title>Quantitative interaction proteomics and genomeâwide profiling of epigenetic histone marks and their readers</article-title>. <source xml:lang="en">Cell</source>
<volume>142</volume>: <fpage>967</fpage>â<lpage>980</lpage>
<pub-id pub-id-type="pmid">20850016</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0050">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0050">
<string-name>
<surname>Watanabe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mii</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Asai</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Asai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Niimi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ushida</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Enomoto</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ishii</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Murakumo</surname>
<given-names>Y</given-names>
</string-name> (<year>2013</year>) <article-title>The Rev7 subunit of DNA polymerase Î¶ is essential for primordial germ cell maintenance in the mouse</article-title>. <source xml:lang="en">J Biol Chem</source>
<volume>288</volume>: <fpage>10459</fpage>â<lpage>10471</lpage>
<pub-id pub-id-type="pmid">23463509</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0051">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0051">
<string-name>
<surname>Wyatt</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Conlin</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Yousefzadeh</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Mieczkowski</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Wood</surname>
<given-names>RD</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Ramsden</surname>
<given-names>DA</given-names>
</string-name> (<year>2016</year>) <article-title>Essential roles for polymerase thetaâmediated end joining in the repair of chromosome breaks</article-title>. <source xml:lang="en">Mol Cell</source>
<volume>63</volume>: <fpage>662</fpage>â<lpage>673</lpage>
<pub-id pub-id-type="pmid">27453047</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0052">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0052">
<string-name>
<surname>Xu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chapman</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Brandsma</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mistrik</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bouwman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bartkova</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gogola</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Warmerdam</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Barazas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jaspers</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Pieterse</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kersbergen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sol</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Celie</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Schouten</surname>
<given-names>PC</given-names>
</string-name>, <string-name>
<surname>van den Broek</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Salman</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nieuwland</surname>
<given-names>M</given-names>
</string-name>
<italic>etÂ al</italic> (<year>2015</year>) <article-title>REV7 counteracts DNA doubleâstrand break resection and affects PARP inhibition</article-title>. <source xml:lang="en">Nature</source>
<volume>521</volume>: <fpage>541</fpage>â<lpage>544</lpage>
<pub-id pub-id-type="pmid">25799992</pub-id></mixed-citation>
      </ref>
      <ref id="embj201899543-bib-0053">
        <mixed-citation publication-type="journal" id="embj201899543-cit-0053">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Willers</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Ghosh</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Weaver</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Powell</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>F</given-names>
</string-name> (<year>2004</year>) <article-title>Chk2 phosphorylation of BRCA1 regulates DNA doubleâstrand break repair</article-title>. <source xml:lang="en">Mol Cell Biol</source>
<volume>24</volume>: <fpage>708</fpage>â<lpage>718</lpage>
<pub-id pub-id-type="pmid">14701743</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>